Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4635223 | 0.91 | MEN1 (0.39) | MEN1KMT2A | |
| SCHEMBL4635225 | 0.79 | KMT2A (0.40) | MEN1KMT2A | |
| SCHEMBL4128848 | 0.76 | MEN1 (0.43) | MEN1KMT2A | |
| SCHEMBL4128846 | 0.76 | MEN1 (0.43) | MEN1KMT2A | |
| SCHEMBL4131927 | 0.72 | KMT2A (0.42) | MEN1KMT2A | |
| SCHEMBL4131931 | 0.72 | KMT2A (0.42) | MEN1KMT2A | |
| SCHEMBL4127484 | 0.71 | MEN1 (0.39) | MEN1KMT2A | |
| SCHEMBL4127491 | 0.71 | MEN1 (0.39) | MEN1KMT2A | |
| SCHEMBL4127235 | 0.71 | KMT2A (0.39) | MEN1KMT2A | |
| SCHEMBL4127754 | 0.68 | KMT2A (0.46) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090088432-A1 | Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors | TORRENT PHARMACEUTICALS LIMITED (IN) | 2009-04-02 | — | — | US | claimed |
| US-20090088432-A1 | Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors | TORRENT PHARMACEUTICALS LIMITED (IN) | 2009-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088432-A1 | Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors | PTPRF, PTPA, PTPRJ | MEN1 4075/4885KMT2A 2895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.